Back to Clinical Trials

Clinical Trials: Clinical Pharmacology & Toxicology


Source: Novartis
To characterize the pharmacokinetics and safety of alpelisib in subjects with hepatic impairment compared to matched healthy control subjects. Read More
Last Updated: 02 Jan 2017
Source: Technische Universität Dresden
Characterization of an unexpected venodilative effect of higher L-NMMA-doses in dorsal human hand veins. Read More
Last Updated: 31 Oct 2005
Source: Pharmacology Research Institute
The purpose is to evaluate the safety and usefulness of the investigational drug, vilazodone in depression. Read More
Last Updated: 07 May 2012
Source: Allergan
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack. Read More
Last Updated: 08 Jan 2017
Source: University Hospital, Clermont-Ferrand
Many large-scale epidemiological studies have established a link between the average consumption of table salt (sodium chloride) and blood pressure. In France a survey conducted in 2001 showed that the average consumption of salt is 9 to 10g per people / day, and health authorities considered it appropriate to reduce consumption about 20%, by limiting contributions of sodium in prepared foods, bread. In terms of basic and clinical research, the biological ... Read More
Last Updated: 24 Jul 2016
Source: Bristol-Myers Squibb
The purpose of this study it to evaluate the long-term safety and tolerability of BMS-820836 in patients with depression. Read More
Last Updated: 22 Sep 2015
Source: Sanofi
The purpose of this study is to assess xaliproden's potential capacity of slowing the deterioration of cognitive and global functions in patients with mild to moderate Alzheimer's disease. The patients participating in this study will take orally once daily xaliproden or placebo (inactive substance pill). Read More
Last Updated: 19 Aug 2008
Source: Stanford University
The purpose of this study is to see whether the medication mifepristone is an effective and tolerable treatment for increasing the clinical effectiveness of electroconvulsive therapy (ECT) and protecting cognitive function during ECT. Both Mifepristone and ECT appear to normalize hyperfunctioning of the hypothalmic-pituitary-adrenal (HPA) axis, which has been found among patients with major depression referred for ECT. The combination of these two treatments ... Read More
Last Updated: 14 Sep 2010
Source: Seattle Genetics, Inc.
The purpose of this study is to identify brentuximab vedotin drug-drug interactions in patients with CD30-positive cancers and to determine the main route of excretion. The study will also assess blood drug levels in patients with renal or hepatic impairment (special populations). Read More
Last Updated: 16 Dec 2014
Source: Chiesi Farmaceutici S.p.A.
The rationale is to investigate the systemic availability of BDP/B17MP and formoterol after single oral inhalation of CHF 1535 50/6 pMDI vs the free combination of approved BDP and Formoterol pMDIs, in asthmatic children (5 to 11 years old). Read More
Last Updated: 06 May 2013
Source: University of Pennsylvania
Cocaine use, abuse and dependence is a public health problem that is directly responsible for hundreds of billions of dollars in health care expenditures per year. Relapse rates to cocaine use are high, creating a pressing need to develop effective therapies for cocaine dependence. The proposed research will focus on investigating the determinants and consequences of cocaine dependence via measurement of physiological, behavioral and subjective effects of ... Read More
Last Updated: 13 Oct 2013
Source: Sunovion
The effect of rifampin on the pharmacokinetics of lurasidone Read More
Last Updated: 05 Sep 2011
Source: University of Southern Denmark
The aim of this study is to investigate if the genetic variant CYP2C19*17 affects the pharmacokinetics of proguanil and clopidogrel. Read More
Last Updated: 01 Jul 2013
Source: University of Jena
The study was conducted to investigate the effect of soluble phosphate in combination with different calcium doses on calcium and phosphorus metabolism and further physiological parameters in healthy subjects. The main aim of the study is to investigate the influence of a soluble phosphate supplementation on the fasting blood phosphate concentration and the dependency of an additional calcium intake. Read More
Last Updated: 29 Nov 2015
Source: Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated is developing LGD-6972, a novel, orally-bioavailable addition to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The mechanism of action of LGD-6972 is to reduce the excess liver glucose production characteristic of type 2 diabetes mellitus that is a major contributor to hyperglycemia. This clinical trial will evaluate the safety and tolerability of escalating doses LGD-6972 ... Read More
Last Updated: 09 Jun 2015
Source: State University of New York at Buffalo
This study is designed to determine the relative effectiveness of buprenorphine/naloxone (Suboxone) pharmacotherapy versus naltrexone pharmacotherapy for treatment retention, relapse prevention and opioid craving reduction among opioid-dependent adolescents and young adults. The investigators hypothesize that naltrexone treatment is as effective as buprenorphine/naloxone for these treatment outcomes. Read More
Last Updated: 05 Jun 2014
Source: Vifor Inc.
The purpose of this study is to determine if Warfarin is affected by PA21. Read More
Last Updated: 13 Feb 2012
Source: Otsuka Pharmaceutical Co., Ltd.
The purpose of this study is to investigate the bioequivalence of ASC-01 Placebo and sertraline Tablet in Japanese healthy male subjects. Read More
Last Updated: 12 Mar 2014
Source: Asahi Kasei Pharma Corporation
This will be a Phase II, multi-centre study consisting of 2 parts. Part 1: Clinical Pharmacology Study (drug-drug interaction between AK106-001616 and methotrexate) Part 2: Proof of Concept Study Read More
Last Updated: 20 Jul 2016
Source: Kaneq Bioscience Limited
This study will consist of multiple ascending oral doses in up to 3 groups, for 29 days. Read More
Last Updated: 12 Sep 2016